Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0002001011-25-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-19 | 2025-02-14+ | LGND | Davis Todd C | CEO, Dir | F - Tax | $120.00 | -13.5K | 130.3K | -9% | -$1.61M |
| 2025-02-19 | 2025-02-14 | LGND | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +20.8K | 143.8K | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-15 | F | D | 2,231 | $120.00 | 134,597 | D | — | — | (F3) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |
| 2 | Common | Common Stock | 2025-02-14 | F | D | 6,966 | $120.00 | 136,828 | D | — | — | (F2) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. |
| 3 | Common | Common Stock | 2025-02-15 | F | D | 4,255 | $120.00 | 130,342 | D | — | — | (F3) Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |
| 4 | Common | Common Stock | 2025-02-14 | A | A | 20,784 | $0.00 | 143,794 | D | — | — | (F1) Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). |